Cancer patient survival in Estonia 1995–2009: Time trends and data quality

Innos, Kaire; Baburin, Aleksei; Aareleid, Tiiu

doi:10.1016/j.canep.2014.03.008

Cited by 22 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sources are used for case ascertainment, including trace-back of cases first identified via death certificates as well as linkages with the databases of cancer centers. The percentage of death certificate only (DCO) cases has been stable and around 2% for all sites and 0.6% for CM [2]. The data quality indicators have been similar for male and female cases [5].…”

Section: Methodsmentioning

confidence: 90%

“…At the same time, the age gradient increased, as younger patients experienced a larger survival gain than older patients. The major strength of this study was the use of high quality data from the ECRfor CM, 99% of cases were microscopically verified and below 1% were DCO cases [2]. Another strength of the study was the availability of data on TNM stage, which is more accurate than the commonly used classification of tumors into localized and advanced stage.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of cutaneous melanoma (CM) is rising in Caucasian populations around the world [1]. The same applies to Estonia, as cancer incidence and survival analyses have shown increased incidence of CM, but also poor survival in international comparisons [2,3]. According to the EUROCARE-5 study, the European mean age-standardized five-year relative survival (RS) of patients diagnosed with CM during 2000-2007 was 83%, but only 72% for Estonia [4].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Padrik

Valter

et al. 2016

Acta Oncologica

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Padrik

Valter

et al. 2016

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…Currently, the ECR follows international definitions and rules, including those for multiple [7], for reporting incidence and survival. Good data quality has been shown for adult cancers [8]. According to a previous study [9], the estimated completeness of reporting of childhood cancer cases was 89.5% (81.2% for hematologic malignancies and 95.3% for solid tumors).…”

Section: Discussionmentioning

confidence: 99%

Childhood cancer incidence and survival trends in Estonia (1970–2016): a nationwide population-based study

et al. 2020

View full text Add to dashboard Cite

Background: Childhood cancers represent a small proportion of all cancers but are still a major public health problem. The study analysed long-term trends in childhood cancer incidence and survival in Estonia in relation to societal and health care transition. Methods: Data on all malignant tumours, diagnosed in children aged 0-14 during 1970-2016, were derived from the Estonian Cancer Registry. Age-standardised (World standard) incidence rates were calculated by ICCC-3 site groups and joinpoint regression was used to estimate annual percentage change (APC) for incidence trends. Cohort and period approach were used to estimate 5-year survival. Internal age standardisation was applied. Results: A total of 1628 incident cancer cases were diagnosed during the study period and overall incidence increased significantly at a rate of 0.5% per year. Significant increases were seen for neuroblastoma and germ cell tumours, for lymphoid leukemias and some CNS sub-sites. At the same time, decline in incidence was seen in almost all subgroups of unspecified neoplasms. The overall 5-year survival improved from 24% in 1970-1979 to 73% in 2010-2016, with the largest changes occurring in the 1990s and 2000s. For many sites, survival increase thereafter has been marginal. Conclusion: In this first comprehensive population-based study of childhood cancer incidence and survival in Estonia, long-term trends are shown in the context of societal and health care changes. Even though the increasing incidence of some sites may, at least partially, be explained by improved diagnostics reflected in the decreased incidence of unspecified neoplasms, the overall cancer incidence in children seems to be rising. Rapid progress in diagnosis and care have improved childhood cancer survival immensely, but deficit in Estonia persists compared to other European countries. Results of the study accentuate the need for a more in-depth analysis of clinical data, but also for the prioritization of childhood cancer in Estonia, to ensure access to standard care and innovative treatments.

show abstract

“…Good data quality has been shown for adult cancers. 8 According to a previous study, 9 the estimated completeness of reporting of childhood cancer cases was 89.5% (81.2% for hematologic malignancies and 95.3% for solid tumors). As a result of the data quality study, all missing cases starting from 2000…”

Section: Incidencementioning

confidence: 96%

Childhood cancer incidence and survival trends in Estonia (1970–2016): a nationwide population-based study

Paapsi

Baburin

Mikkel

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Childhood cancers represent a small proportion of all cancers but are still a major public health problem. The study analysed long-term trends in childhood cancer incidence and survival in Estonia in relation to societal and health care transition. Methods: Data on all malignant tumours, diagnosed in children aged 0–14 during 1970–2016, were derived from the Estonian Cancer Registry. Age-standardised (World standard) incidence rates were calculated by ICCC-3 site groups and joinpoint regression was used to estimate annual percentage change (APC) for incidence trends. Cohort and period approach were used to estimate 5-year survival. Internal age standardisation was applied. Results: A total of 1628 incident cancer cases were diagnosed during the study period and overall incidence increased significantly at a rate of 0.5% per year. Significant increases were seen for neuroblastoma and germ cell tumours, for lymphoid leukemias and some CNS sub-sites. At the same time, decline in incidence was seen in almost all subgroups of unspecified neoplasms. The overall 5-year survival improved from 24% in 1970–1979 to 73% in 2010–2016, with the largest changes occurring in the 1990s and 2000s. For many sites, survival increase thereafter has been marginal. Conclusion: In this first comprehensive population-based study of childhood cancer incidence and survival in Estonia, long-term trends are shown in the context of societal and health care changes. Even though the increasing incidence of some sites may, at least partially, be explained by improved diagnostics reflected in the decreased incidence of unspecified neoplasms, the overall cancer incidence in children seems to be rising. Rapid progress in diagnosis and care have improved childhood cancer survival immensely, but deficit in Estonia persists compared to other European countries. Results of the study accentuate the need for a more in-depth analysis of clinical data, but also for the prioritization of childhood cancer in Estonia, to ensure access to standard care and innovative treatments.

show abstract

Cancer patient survival in Estonia 1995–2009: Time trends and data quality

Cited by 22 publications

References 39 publications

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Childhood cancer incidence and survival trends in Estonia (1970–2016): a nationwide population-based study

Childhood cancer incidence and survival trends in Estonia (1970–2016): a nationwide population-based study

Contact Info

Product

Resources

About